Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Oct 2;72(14):1563-1572.
doi: 10.1016/j.jacc.2018.07.046.

Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization: The EUCLID Trial

Iris Baumgartner  1 , Lars Norgren  2 , F Gerry R Fowkes  3 , Hillary Mulder  4 , Manesh R Patel  4 , Jeffrey S Berger  5 , W Schuyler Jones  4 , Frank W Rockhold  4 , Brian G Katona  6 , Kenneth Mahaffey  7 , William R Hiatt  8 ; Executive Committee and Investigators of the EUCLID Trial
Affiliations
Free article
Randomized Controlled Trial

Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization: The EUCLID Trial

Iris Baumgartner et al. J Am Coll Cardiol. .
Free article

Abstract

Background: Lower extremity revascularization (LER) is a common treatment in patients with peripheral artery disease (PAD), but long-term outcomes are poorly defined.

Objectives: The aim was to analyze LER in the EUCLID (Examining Use of tiCagreLor In paD) trial to determine predictors and cardiovascular outcomes.

Methods: Patients were grouped according to whether they received a post-randomization LER (n = 1,738) or not (n = 12,147). All variables were assessed for significance in univariable and parsimonious multivariable models. The primary endpoint was myocardial infarction, ischemic stroke, or cardiovascular death; major adverse limb events (MALE) included acute limb ischemia or major amputation.

Results: A post-randomization LER occurred in 12.5% of patients and was an endovascular LER in 74.7%. Endovascular LERs were performed more often in North America, whereas surgical procedures occurred more frequently in Europe. Independent factors predicting LER were prior and type of prior LER, geographic region, limb symptoms, diabetes, and smoking. A post-randomization LER was associated with an increased risk for the primary endpoint (hazard ratio: 1.60; 95% confidence interval: 1.35 to 1.90; p < 0.0001) and MALE (hazard ratio: 12.0; 95% confidence interval: 9.47 to 15.30; p < 0.0001). Event rates for the primary endpoint after LER were numerically higher in the surgical subgroup, but MALE were similar between surgical and endovascular LER.

Conclusions: In the EUCLID trial, LER was most often endovascular. Following LER, there was an increased hazard for the primary endpoint (with higher event rates in the surgical group) and a markedly increased risk for MALE events (with similar event rates between surgical and endovascular LER procedures). (A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease [EUCLID]; NCT01732822).

Keywords: acute limb ischemia; cardiovascular event; diabetes; lower extremity revascularization; peripheral artery disease; smoking.

PubMed Disclaimer

Comment in

  • The Future Is Determined Now.
    Moneta GL. Moneta GL. J Am Coll Cardiol. 2018 Oct 2;72(14):1573-1575. doi: 10.1016/j.jacc.2018.04.095. J Am Coll Cardiol. 2018. PMID: 30261956 No abstract available.

Publication types

Associated data